Objective:To investigate the effectiveness and efficiency of combining levamlodipine besylate and valsartan in the treatment of hypertension.Methods:This study selected 28 patients with hypertension as observation sub...Objective:To investigate the effectiveness and efficiency of combining levamlodipine besylate and valsartan in the treatment of hypertension.Methods:This study selected 28 patients with hypertension as observation subjects.The treatment duration ranged from January 2020 to June 2023.Using the random number table method,patients were divided into two groups.The control group received treatment with valsartan,while the observation group received a combination of valsartan and levamlodipine besylate.Therapeutic effects and safety were compared between the groups,and changes in the patient’s blood pressure and renal function index levels were assessed.Results:The total clinical effective rate of the observation group was significantly higher than that of the control group(P<0.05).The observation group demonstrated better diastolic blood pressure,systolic blood pressure,and renal function indicators compared to the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combined treatment of levamlodipine besylate and valsartan in patients with hypertension showed significant clinical efficacy and holds broad application value.展开更多
文摘Objective:To investigate the effectiveness and efficiency of combining levamlodipine besylate and valsartan in the treatment of hypertension.Methods:This study selected 28 patients with hypertension as observation subjects.The treatment duration ranged from January 2020 to June 2023.Using the random number table method,patients were divided into two groups.The control group received treatment with valsartan,while the observation group received a combination of valsartan and levamlodipine besylate.Therapeutic effects and safety were compared between the groups,and changes in the patient’s blood pressure and renal function index levels were assessed.Results:The total clinical effective rate of the observation group was significantly higher than that of the control group(P<0.05).The observation group demonstrated better diastolic blood pressure,systolic blood pressure,and renal function indicators compared to the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combined treatment of levamlodipine besylate and valsartan in patients with hypertension showed significant clinical efficacy and holds broad application value.
